A growing industry like BosterBio today is not just a guess. In a 2011 report total sales between biopharmaceutical companies exceeded $ 100 billion in 2010. However, the industry is far from being at the forefront, as companies are expected to increase costs to $ 200 billion by 2015, which is a big difference between the demand for cell line development and the ability of global pharmaceutical companies to create new capacities. built to fill this gap. 

This problem affects large multinational corporations nothing more than small companies that can no longer afford to invest in these facilities or take over the remaining multinational companies. If you are looking for monoclonal antibody production companies visit https://www.bosterbio.com/services/custom-monoclonal-antibody-development-service for details.

Hence, the number of contracting organizations is growing very rapidly as they allow smaller biopharmaceutical companies to compete. Of course, large companies also outsource some of their production requirements to cut costs and ensure that new product lines are sold religiously. 

In fact, biology makes up more than 3 in 10 of the drugs developed worldwide. Companies have found the benefit of outsourcing their needs to develop cell lines, biosimilar, or bio-enhancers.

It’s easy to believe the market is saturated with CMOS, but you’d be wrong. For example, between 2011 and 2018, a biofilm (or one of the top 30 bioproducts) worth the US $ 30 billion had to lose its patent protection in Europe alone. Free for everyone, this means passion to develop similar products that can be cheaper and better.